While progress is being made toward the goal of personalized medicine for cancer patients, much work remains, writes Rachael Rettner at MyHealthNewsDaily. "We're much better than we were a decade ago" at tailoring patients' treatments, Monter Cancer Center's Daniel Budman tells Rettner. Much of this progress is being fueled by advances in genome sequencing — which is falling quickly in price — as sequencing can be used to find the mutations in a particular patient's tumor. Marc Symons from the Feinstein Institute for Medical Research adds that the main hurdle is determining which mutations affect the course of the disease and finding drugs that target those mutations.
Getting Closer, But Work Remains
Dec 28, 2011